[go: up one dir, main page]

ATE389721T1 - Agonistische antikörper gegen den thrombopoietinrezeptor und deren therapeutische verwendungen - Google Patents

Agonistische antikörper gegen den thrombopoietinrezeptor und deren therapeutische verwendungen

Info

Publication number
ATE389721T1
ATE389721T1 AT98939976T AT98939976T ATE389721T1 AT E389721 T1 ATE389721 T1 AT E389721T1 AT 98939976 T AT98939976 T AT 98939976T AT 98939976 T AT98939976 T AT 98939976T AT E389721 T1 ATE389721 T1 AT E389721T1
Authority
AT
Austria
Prior art keywords
therapeutic uses
agonistic antibodies
thrombopoietin receptor
receptor
thrombopoietin
Prior art date
Application number
AT98939976T
Other languages
English (en)
Inventor
Camellia Adams
Paul Carter
Brian Fendly
Austin Gurney
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE389721T1 publication Critical patent/ATE389721T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT98939976T 1997-08-25 1998-08-21 Agonistische antikörper gegen den thrombopoietinrezeptor und deren therapeutische verwendungen ATE389721T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/918,148 US6342220B1 (en) 1997-08-25 1997-08-25 Agonist antibodies

Publications (1)

Publication Number Publication Date
ATE389721T1 true ATE389721T1 (de) 2008-04-15

Family

ID=25439886

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98939976T ATE389721T1 (de) 1997-08-25 1998-08-21 Agonistische antikörper gegen den thrombopoietinrezeptor und deren therapeutische verwendungen

Country Status (9)

Country Link
US (1) US6342220B1 (de)
EP (2) EP1009831B1 (de)
JP (1) JP2001513999A (de)
AT (1) ATE389721T1 (de)
AU (1) AU755822B2 (de)
CA (1) CA2301964C (de)
DE (1) DE69839270T2 (de)
ES (1) ES2304795T3 (de)
WO (1) WO1999010494A2 (de)

Families Citing this family (200)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US7531643B2 (en) * 1997-09-11 2009-05-12 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody inducing apoptosis
TWI242563B (en) * 1998-04-30 2005-11-01 Tanox Inc Monoclonal agonist antibodies which specifically bind to or interact with human G-CSF receptor
CZ302155B6 (cs) 1998-10-23 2010-11-18 Kirin-Amgen Inc. Sloucenina, která se váže na mpl receptor, zpusob její výroby, farmaceutická kompozice s jejím obsahem, polynukleotid, vektor a hostitelská bunka
US7696325B2 (en) * 1999-03-10 2010-04-13 Chugai Seiyaku Kabushiki Kaisha Polypeptide inducing apoptosis
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
JP2003509478A (ja) 1999-09-21 2003-03-11 エモリー・ユニバーシティ 血小板関連障害を処置する方法および組成物
USD464436S1 (en) * 1999-11-19 2002-10-15 Fox Lite, Inc. Collapsible skylight tube having open ends and a light reflecting inner surface
AU7390601A (en) * 2000-03-30 2001-10-08 Novartis Ag Selectable marker genes
EP1149906A1 (de) * 2000-04-25 2001-10-31 Pliva, Farmaceutska, Industrija, Dionicko Drustvo Thrombopoietin Rezeptormodulations Peptide
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
WO2002002641A1 (en) 2000-06-16 2002-01-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys
GB0014878D0 (en) * 2000-06-16 2000-08-09 Isis Innovation Neurotransmission disorders
EP1294879B1 (de) 2000-06-28 2008-12-31 Amgen Inc. Thymus-stroma lymphopoietin rezeptor-moleküle und deren verwendung
AU2001288301A1 (en) 2000-08-18 2002-03-04 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
US7064191B2 (en) * 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
JPWO2002030954A1 (ja) * 2000-10-06 2004-02-19 協和醗酵工業株式会社 抗体を精製する方法
ATE391174T1 (de) * 2000-10-20 2008-04-15 Chugai Pharmaceutical Co Ltd Modifizierter tpo-agonisten antikörper
KR100870123B1 (ko) * 2000-10-20 2008-11-25 츄가이 세이야꾸 가부시키가이샤 저분자화 아고니스트 항체
ES2380367T3 (es) 2000-12-05 2012-05-11 Alexion Pharmaceuticals, Inc. Anticuerpos diseñados racionalmente
AU2003295623B2 (en) * 2000-12-05 2008-06-05 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
US7396917B2 (en) * 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
WO2002077172A2 (en) * 2001-03-23 2002-10-03 Board Of Regents, The University Of Texas System Methods for inhibition of angiogenesis, tumor growth and metastasis by fully human anti-il8 and anti-muc18 in diverse types of tumors
AU2002326751A1 (en) * 2001-08-13 2003-03-03 Ige Therapeutics, Inc. Immunoglobulin e vaccines and methods of use thereof
KR100467750B1 (ko) * 2001-11-29 2005-01-24 씨제이 주식회사 생체내 에리스로포이에틴 활성이 증진된 융합단백질
ES2307824T3 (es) * 2001-12-28 2008-12-01 Amgen Fremont Inc. Uso de anticuerpos contra el antigeno muc18.
JP2005516965A (ja) * 2001-12-28 2005-06-09 アブジェニックス・インコーポレーテッド 抗ｍｕｃ１８抗体を使用する方法
US20050069549A1 (en) 2002-01-14 2005-03-31 William Herman Targeted ligands
GB0202206D0 (en) * 2002-01-31 2002-03-20 Bioinvent Int Ab Method of making libraries of anti-ligands
US7662924B2 (en) 2002-02-22 2010-02-16 The Board Of Trustees Of The University Of Illinois Beta chain-associated regulator of apoptosis
ATE439861T1 (de) 2002-03-15 2009-09-15 Schering Corp Verfahren zur modulierung von cd200-rezeptoren
WO2003091424A1 (fr) 2002-04-26 2003-11-06 Chugai Seiyaku Kabushiki Kaisha Procede de criblage d'un anticorps agoniste
WO2004003144A2 (en) * 2002-07-01 2004-01-08 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
WO2004013287A2 (en) * 2002-08-02 2004-02-12 Human Genome Sciences, Inc. Antibodies against c3a receptor
US20040028661A1 (en) * 2002-08-07 2004-02-12 Bartelmez Stephen H. Expansion of cells using thrombopoietin and anti-transforming growth factor-beta
EA033750B1 (ru) 2002-09-06 2019-11-21 Amgen Inc Изолированная молекула нуклеиновой кислоты, кодирующая антитело человека к рецептору интерлейкина-1, и ее применение
EP1561759B9 (de) * 2002-10-11 2009-08-26 Chugai Seiyaku Kabushiki Kaisha Zelltod-induzierender wirkstoff
WO2004081048A1 (ja) * 2003-03-13 2004-09-23 Chugai Seiyaku Kabushiki Kaisha 変異受容体に対するアゴニスト活性を有するリガンド
JP2004279086A (ja) * 2003-03-13 2004-10-07 Konica Minolta Holdings Inc 放射線画像変換パネル及び放射線画像変換パネルの製造方法
WO2004087763A1 (ja) * 2003-03-31 2004-10-14 Chugai Seiyaku Kabushiki Kaisha Ｃｄ２２に対する改変抗体およびその利用
JP4794301B2 (ja) * 2003-06-11 2011-10-19 中外製薬株式会社 抗体の製造方法
WO2005033134A2 (en) * 2003-09-30 2005-04-14 Regeneron Pharmaceuticals, Inc. Secreted protein therapeutics and uses thereof
AU2003271174A1 (en) 2003-10-10 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
KR20060130606A (ko) * 2003-12-12 2006-12-19 추가이 세이야쿠 가부시키가이샤 세포사 유도제
WO2005056602A1 (ja) * 2003-12-12 2005-06-23 Chugai Seiyaku Kabushiki Kaisha アゴニスト活性を有する改変抗体のスクリーニング方法
TW200530269A (en) * 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
WO2005100560A1 (ja) * 2004-04-09 2005-10-27 Chugai Seiyaku Kabushiki Kaisha 細胞死誘導剤
TW200605906A (en) * 2004-05-11 2006-02-16 Chugai Pharmaceutical Co Ltd Remedy for thrombopenia
US7709611B2 (en) 2004-08-04 2010-05-04 Amgen Inc. Antibodies to Dkk-1
US20060134698A1 (en) 2004-12-20 2006-06-22 Evanston Northwestern Healthcare Research Institute Methods for treating cardiac disease by modifying an N-terminal domain of troponin I
US20060275288A1 (en) * 2005-01-20 2006-12-07 Grihalde Nelson D GLP-1 receptor agonist and allosteric modulator monoclonal antibodies and uses thereof
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
JP5620626B2 (ja) 2005-03-31 2014-11-05 中外製薬株式会社 会合制御によるポリペプチド製造方法
WO2006106903A1 (ja) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha sc(Fv)2構造異性体
WO2006123724A1 (ja) * 2005-05-18 2006-11-23 The University Of Tokushima 抗hla抗体を利用した新規医薬品
JP5085322B2 (ja) 2005-06-10 2012-11-28 中外製薬株式会社 ｓｃ（Ｆｖ）２を含有する医薬組成物
JP5068167B2 (ja) * 2005-06-10 2012-11-07 中外製薬株式会社 メグルミンを含有するタンパク質製剤の安定化剤、およびその利用
WO2006132341A1 (ja) * 2005-06-10 2006-12-14 Chugai Seiyaku Kabushiki Kaisha sc(Fv)2部位特異的変異体
CA2616395C (en) 2005-07-25 2016-10-04 Trubion Pharmaceuticals B-cell reduction using cd37-specific and cd20-specific binding molecules
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
AU2007208226A1 (en) * 2006-01-25 2007-08-02 Amgen Inc. Thrombopoietic compounds
WO2007111661A2 (en) 2006-03-20 2007-10-04 Xoma Technology Ltd. Human antibodies specific for gastrin materials and methods
CA2644663A1 (en) 2006-03-23 2007-09-27 Kirin Pharma Kabushiki Kaisha Agonist antibody to human thrombopoietin receptor
EP3056568B1 (de) 2006-03-31 2021-09-15 Chugai Seiyaku Kabushiki Kaisha Verfahren zur kontrolle der blutpharmakokinetik von antikörpern
EP3345616A1 (de) * 2006-03-31 2018-07-11 Chugai Seiyaku Kabushiki Kaisha Antikörpermodifizierungsverfahren zur reinigung von bispezifischem antikörper
US8211649B2 (en) 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma
EP3805269A1 (de) 2006-06-12 2021-04-14 Aptevo Research and Development LLC Einkettige, multivalente bindungsproteine mit effektorfunktion
AU2007259739B2 (en) * 2006-06-14 2013-03-07 Chugai Seiyaku Kabushiki Kaisha Agents for promoting the growth of hematopoietic stem cells
US20100150927A1 (en) * 2006-07-13 2010-06-17 Chugai Seiyaku Kabushiki Kaisha Cell death inducer
JP5645409B2 (ja) 2006-12-20 2014-12-24 ゾーマ （ユーエス） リミテッド ライアビリティ カンパニー ＩＬ−１β関連疾患の治療方法
ES2910298T3 (es) * 2007-03-08 2022-05-12 Humanigen Inc Anticuerpos contra EphA3 para el tratamiento de tumores sólidos
CL2008000719A1 (es) * 2007-03-12 2008-09-05 Univ Tokushima Chugai Seiyaku Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
PL2188313T3 (pl) 2007-08-21 2018-04-30 Amgen, Inc. Białka wiążące ludzki antygen c-fms
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
US9096651B2 (en) 2007-09-26 2015-08-04 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
WO2009064944A2 (en) 2007-11-16 2009-05-22 Nuvelo, Inc. Antibodies to lrp6
PL2391650T3 (pl) 2007-12-20 2015-03-31 Xoma Us Llc Sposoby leczenia dny
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
KR20110013391A (ko) 2008-04-11 2011-02-09 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 Ｃｄ37 면역치료제 및 이작용성 화학치료제와 이의 병용물
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
EP2671891A3 (de) 2008-06-27 2014-03-05 Amgen Inc. Ang-2-Hemmung zur Behandlung von Multipler Sklerose
JP5878757B2 (ja) 2008-10-10 2016-03-08 アムジエン・インコーポレーテツド Ｆｇｆ２１変異体およびその使用
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
EP2427207B1 (de) 2009-05-05 2017-08-16 Amgen, Inc Fgf21-mutanten und ihre verwendungen
NZ596037A (en) 2009-05-05 2013-10-25 Amgen Inc Fgf21 mutants and uses thereof
EP3009455A1 (de) 2009-09-16 2016-04-20 Immunomedics Inc. Klasse-i-anti-cea-antikörper und verwendungen davon
CN102597775A (zh) 2009-09-25 2012-07-18 佐马技术有限公司 筛选方法
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
US9517264B2 (en) 2010-04-15 2016-12-13 Amgen Inc. Human FGF receptor and β-Klotho binding proteins
SG10201911345WA (en) 2010-05-04 2020-01-30 Five Prime Therapeutics Inc Antibodies that bind csf1r
JP6030052B2 (ja) 2010-05-14 2016-11-24 バクスアルタ インコーポレイテッド Ｏｓｐａキメラおよびそのワクチンでの使用法
GB201012410D0 (en) 2010-07-23 2010-09-08 Medical Res Council Intracellular immunity
GB201012420D0 (en) 2010-07-23 2010-09-08 Univ Erasmus Medical Ct Foetal heamoglobin inhibitor
MX354481B (es) 2010-10-27 2018-03-07 Amgen Inc Anticuerpos dkk1 y métodos de uso.
TWI452135B (zh) 2010-11-17 2014-09-11 中外製藥股份有限公司 A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
EP2663578A2 (de) 2011-01-14 2013-11-20 Five Prime Therapeutics, Inc. Il-27 antagonisten zur behandlung von entzündungserkrankungen
WO2012118903A2 (en) 2011-03-01 2012-09-07 Amgen Inc. Bispecific binding agents
JP2014515476A (ja) * 2011-05-20 2014-06-30 アボットジャパン株式会社 非特異的結合を減少させるためのイムノアッセイ方法及び試薬
AU2012261933B2 (en) 2011-06-03 2017-06-15 Xoma Technology Ltd. Antibodies specific for TGF-beta
US9574002B2 (en) 2011-06-06 2017-02-21 Amgen Inc. Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
AU2012271329A1 (en) 2011-06-17 2013-12-19 Amgen Inc. Method of treating or ameliorating metabolic disorders using Clec-2
WO2013074636A1 (en) * 2011-11-14 2013-05-23 New York University Muscle specific receptor kinase and modulation thereof
MX368200B (es) 2011-12-08 2019-09-24 Amgen Inc Proteinas de union al antigeno lecitin colesterol aciltransferasas humanas agonistas y su uso en terapia.
CN104144946A (zh) 2011-12-19 2014-11-12 爱克索马美国有限责任公司 治疗痤疮的方法
GB201202268D0 (en) 2012-02-09 2012-03-28 Medical Res Council Intracellular immunity
KR102213694B1 (ko) 2012-04-27 2021-02-09 노보 노르디스크 에이/에스 사람 cd30 리간드 항원 결합 단백질
JP2015517490A (ja) 2012-05-11 2015-06-22 ファイブ プライム セラピューティックス インコーポレイテッド コロニー刺激因子１受容体（ｃｓｆ１ｒ）を結合させる抗体を用いて状態を治療する方法
EP3578660A1 (de) * 2012-07-05 2019-12-11 F. Hoffmann-La Roche AG Expressions- und sekretionssystem
CN104640563A (zh) 2012-07-27 2015-05-20 巴克斯特国际公司 包含嵌合的ospa分子的组合物及其使用方法
US9074186B2 (en) 2012-08-15 2015-07-07 Boston Medical Center Corporation Production of red blood cells and platelets from stem cells
RU2718751C2 (ru) 2012-08-31 2020-04-14 Файв Прайм Терапьютикс, Инк. Способы лечения патологических состояний антителами, которые связываются с рецептором колониестимулирующего фактора 1 (csf1r)
PT2890836T (pt) * 2012-08-31 2019-09-16 Scripps Research Inst Métodos relacionados a moduladores de células eucariotóticas
US20140271629A1 (en) 2013-03-14 2014-09-18 Amgen Inc. Chrdl-1 antigen binding proteins and methods of treatment
US9676851B2 (en) 2013-03-15 2017-06-13 Amgen Inc. Human PAC1 antibodies
US9850297B2 (en) 2013-03-15 2017-12-26 Amgen Inc. Secreted frizzle-related protein 5 (SFRP5) binding proteins
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
SG11201602261VA (en) 2013-09-27 2016-04-28 Chugai Pharmaceutical Co Ltd Method for producing polypeptide heteromultimer
EP3467501B1 (de) 2014-05-16 2020-11-04 Amgen Inc. Test zum nachweis von th1- und th2-zellpopulationen
BR112016029460A2 (pt) 2014-06-23 2017-10-24 Five Prime Therapeutics Inc métodos para tratar artrite reumatoide
WO2016040767A2 (en) 2014-09-12 2016-03-17 Amgen Inc. Chrdl-1 epitopes and antibodies
US10080790B2 (en) 2014-09-19 2018-09-25 The Regents Of The University Of Michigan Staphylococcus aureus materials and methods
TWI701435B (zh) 2014-09-26 2020-08-11 日商中外製藥股份有限公司 測定ｆｖｉｉｉ的反應性之方法
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
TWI700300B (zh) 2014-09-26 2020-08-01 日商中外製藥股份有限公司 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體
US9765147B2 (en) 2014-10-29 2017-09-19 Five Prime Therapeutics, Inc. Anti-CSFR1 antibody and anti PD-1 antibody combination therapy for cancer
EP3223865A4 (de) 2014-10-31 2018-10-03 Jounce Therapeutics, Inc. Verfahren zur behandlung von erkrankungen mit b7-h4-bindenden antikörpern
AU2015369854B2 (en) 2014-12-22 2021-07-01 Five Prime Therapeutics, Inc. Anti-CSF1R antibodies for treating PVNS
US20160200815A1 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
WO2016141111A1 (en) 2015-03-03 2016-09-09 Xoma (Us) Llc Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
LT3273992T (lt) 2015-03-23 2020-10-26 Jounce Therapeutics, Inc. Antikūnai, atpažįstantys icos
WO2016159213A1 (ja) 2015-04-01 2016-10-06 中外製薬株式会社 ポリペプチド異種多量体の製造方法
ES2820768T3 (es) 2015-04-03 2021-04-22 Xoma Technology Ltd Tratamiento del cáncer usando inhibidores de TGF-beta y PD-1
HUE053903T2 (hu) 2015-04-13 2021-07-28 Five Prime Therapeutics Inc Kombinációs terápia rák ellen
WO2016179194A1 (en) 2015-05-04 2016-11-10 Jounce Therapeutics, Inc. Lilra3 and method of using the same
CN108136006A (zh) 2015-08-06 2018-06-08 佐马美国有限公司 针对胰岛素受体的抗体片段和其治疗低血糖的用途
JP7002446B2 (ja) 2015-09-21 2022-03-04 アプティーボ リサーチ アンド デベロップメント エルエルシー Ｃｄ３結合ポリペプチド
EP3355908A1 (de) 2015-10-01 2018-08-08 Amgen Inc. Behandlung von gallensäureerkrankungen
CN108350505A (zh) 2015-10-22 2018-07-31 震动疗法股份有限公司 用于测定icos表达的基因标志
JP7349787B2 (ja) 2015-11-23 2023-09-25 ファイヴ プライム セラピューティクス インク 癌治療におけるｆｇｆｒ２阻害剤単独または免疫刺激剤との組み合わせ
CR20180378A (es) 2015-12-23 2018-12-06 Amgen Inc Método para tratar o mejorar trastornos metabólicos con proteínas de unión para el receptor peptídico inhibidor gástrico (gipr) en combinación con agosnistas de glp-1
US20200270363A1 (en) 2015-12-25 2020-08-27 Chugai Seiyaku Kabushiki Kaisha Antibody having enhanced activity, and method for modifying same
SG11201803989WA (en) 2015-12-28 2018-06-28 Chugai Pharmaceutical Co Ltd Method for promoting efficiency of purification of fc region-containing polypeptide
WO2017172981A2 (en) 2016-03-29 2017-10-05 University Of Southern California Chimeric antigen receptors targeting cancer
WO2018005950A1 (en) 2016-07-01 2018-01-04 Five Prime Therapeutics, Inc. Combined anti tumor therapy with a gitr agonist and cpg
JP7148493B2 (ja) 2016-08-01 2022-10-05 ゾーマ （ユーエス） リミテッド ライアビリティ カンパニー 副甲状腺ホルモン受容体１（ｐｔｈ１ｒ）抗体およびその使用
CA3035327A1 (en) 2016-09-06 2018-03-15 Chugai Seiyaku Kabushiki Kaisha Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x
EP3518969A2 (de) 2016-09-28 2019-08-07 Xoma (Us) Llc Antikörper zur bindung von interleukin-2 und verwendungen davon
AU2017355401A1 (en) 2016-11-02 2019-05-02 Jounce Therapeutics, Inc. Antibodies to PD-1 and uses thereof
WO2018091720A1 (en) 2016-11-21 2018-05-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the prophylactic treatment of metastases
EA039807B1 (ru) 2017-01-06 2022-03-16 ЭйБиЭл БИО ИНК. Антитело к -синуклеину и его применение
WO2018128454A1 (ko) 2017-01-06 2018-07-12 에이비엘바이오 주식회사 항 α-SYN 항체 및 그 용도
JOP20190177A1 (ar) 2017-01-17 2019-07-16 Amgen Inc طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
EP3601353A1 (de) 2017-03-31 2020-02-05 Five Prime Therapeutics, Inc. Kombinationstherapie gegen krebs mit anti-gitr-antikörpern
JP7299842B2 (ja) 2017-05-16 2023-06-28 ファイヴ プライム セラピューティクス インク がん治療における化学療法剤と組み合わせた抗ｆｇｆｒ２抗体
EP3630836A1 (de) 2017-05-31 2020-04-08 Elstar Therapeutics, Inc. Multispezifische moleküle, die an myeloproliferatives leukämie (mlp)-protein binden, und deren verwendungen
JOP20190259A1 (ar) 2017-05-31 2019-10-31 Amgen Inc بروتينات ربط مولد ضد مضادة لـ jagged1
PE20200013A1 (es) 2017-06-20 2020-01-06 Amgen Inc Metodo para tratar o mejorar trastornos metabolicos con proteinas de union para el receptor peptidico inhibidor gastrico (gipr) en combinacion con agonistas de glp-1
EP3658581A1 (de) 2017-07-24 2020-06-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Antikörper und peptide zur behandlung von erkrankungen im zusammenhang mit hcmv
LT3661562T (lt) 2017-08-04 2024-10-25 Amgen Inc. Cys-mab konjugavimo būdas
US20200256880A1 (en) 2017-08-16 2020-08-13 The Broad Institute, Inc. Neuronal Assay Method Involving Calcineurin
CN111479586A (zh) 2017-09-13 2020-07-31 戊瑞治疗有限公司 用于胰腺癌的组合抗csf1r和抗pd-1抗体的组合疗法
MY204641A (en) 2017-09-29 2024-09-06 Chugai Pharmaceutical Co Ltd Multispecific antigen-binding molecule having blood coagulation factor viii (fviii) cofactor function-substituting activity, and pharmaceutical formulation containing said molecule as active ingredient
US11365250B2 (en) 2017-11-29 2022-06-21 The Board Of Regents Of The University Of Texas System Compositions and methods for cancer therapy
CN116731173A (zh) 2017-12-14 2023-09-12 Abl生物公司 抗a-syn/igf1r的双特异性抗体及其用途
EP3728318A2 (de) 2017-12-22 2020-10-28 Jounce Therapeutics, Inc. Antikörper für lilrb2
JP7437317B2 (ja) 2018-04-02 2024-02-22 アラマブ セラピューティクス， インコーポレイテッド コネキシン４３抗体およびその使用
WO2019225777A1 (ko) 2018-05-23 2019-11-28 에이비엘바이오 주식회사 항-ror1 항체 및 그 용도
WO2019225787A1 (ko) 2018-05-24 2019-11-28 에이비엘바이오 주식회사 항-b7-h3 항체 및 그 용도
EP3820904A2 (de) 2018-07-09 2021-05-19 Five Prime Therapeutics, Inc. An ilt4 bindende antikörper
WO2020089203A1 (en) 2018-10-29 2020-05-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Composition for the treatment of antibody deficiencies
JP2022512860A (ja) 2018-11-06 2022-02-07 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 白血病幹細胞を根絶することによる急性骨髄性白血病の治療のための方法および医薬組成物
WO2020120786A1 (en) 2018-12-14 2020-06-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Isolated mhc-derived human peptides and uses thereof for stimulating and activating the suppressive function of cd8+cd45rclow tregs
WO2020163353A1 (en) 2019-02-04 2020-08-13 Alamab Therapeutics, Inc. Connexin 43 antibodies and use thereof
WO2020169472A2 (en) 2019-02-18 2020-08-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of inducing phenotypic changes in macrophages
CA3130765A1 (en) * 2019-02-26 2020-09-03 Sorrento Therapeutics, Inc. Antigen binding proteins that bind bcma
JP7348676B2 (ja) 2019-06-14 2023-09-21 エービーエル バイオ インコーポレイテッド α－ｓｙｎ／ＩＧＦ１Ｒに対する二重特異抗体およびその用途
WO2021058729A1 (en) 2019-09-27 2021-04-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-müllerian inhibiting substance type i receptor antibodies and uses thereof
CN114450304B (zh) 2019-09-27 2023-12-12 国家医疗保健研究所 抗苗勒管抑制物质抗体及其用途
EP4045044A1 (de) 2019-10-18 2022-08-24 The Regents Of The University Of California Plxdc-aktivatoren und ihre verwendung zur behandlung von blutgefässstörungen
EP4061944A1 (de) 2019-11-22 2022-09-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Inhibitoren von adrenomedullin zur behandlung von akuter myeloischer leukämie durch vernichtung von leukämischen stammzellen
BR112022011993A2 (pt) 2019-12-26 2022-09-20 Abl Bio Inc Método para purificar peptídeo biologicamente ativo usando cromatografia de afinidade de proteína a
EP4087874A1 (de) 2020-01-06 2022-11-16 HiFiBiO (HK) Limited Anti-tnfr2-antikörper und verwendungen davon
IL294466A (en) 2020-01-07 2022-09-01 Hifibio Hk Ltd Anti-galectin-9 antibody and uses thereof
CN115087488A (zh) 2020-02-14 2022-09-20 震动疗法股份有限公司 与ccr8结合的抗体和融合蛋白及其用途
GB202003444D0 (en) * 2020-03-10 2020-04-22 argenx BV Musk agonist antibody
EP4149558A1 (de) 2020-05-12 2023-03-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Neues verfahren zur behandlung von kutanen t-zell-lymphomen und tfh-abgeleiteten lymphomen
EP4192866A2 (de) 2020-08-10 2023-06-14 GV20 Therapeutics LLC Zusammensetzungen und verfahren zur behandlung von autoimmunerkrankungen und krebs durch targeting von igsf8
AU2021360782A1 (en) 2020-10-14 2023-06-08 Five Prime Therapeutics, Inc. Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
WO2023139292A1 (en) 2022-01-24 2023-07-27 Cambridge Enterprise Limited Tau therapy
WO2023235699A1 (en) 2022-05-31 2023-12-07 Jounce Therapeutics, Inc. Antibodies to lilrb4 and uses thereof
US20240165227A1 (en) 2022-11-04 2024-05-23 Gilead Sciences, Inc. Anticancer therapies using anti-ccr8 antibody, chemo and immunotherapy combinations
WO2024233353A1 (en) * 2023-05-05 2024-11-14 The Board Of Trustees Of The Leland Stanford Junior University Method and composition for assessing and enhancing the durability of antibody response to vaccination
WO2024236156A1 (en) 2023-05-17 2024-11-21 Institut National de la Santé et de la Recherche Médicale Anti-cathepsin-d antibodies
WO2024256583A1 (en) 2023-06-14 2024-12-19 Immutrin Ltd Anti-fibril antibodies
WO2025012417A1 (en) 2023-07-13 2025-01-16 Institut National de la Santé et de la Recherche Médicale Anti-neurotensin long fragment and anti-neuromedin n long fragment antibodies and uses thereof
WO2025032158A1 (en) 2023-08-08 2025-02-13 Institut National de la Santé et de la Recherche Médicale Method to treat tauopathies
WO2025050009A2 (en) 2023-09-01 2025-03-06 Children's Hospital Medical Center Identification of targets for immunotherapy in melanoma using splicing-derived neoantigens

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
US4626507A (en) 1980-09-25 1986-12-02 The Salk Institute For Biological Studies Hybridomas producing monoclonal antibodies specific for a human cell surface glycoprotein
ATE12348T1 (de) 1980-11-10 1985-04-15 Gersonde Klaus Prof Dr Verfahren zur herstellung von lipid-vesikeln durch ultraschallbehandlung, anwendung des verfahrens und vorrichtung zur durchfuehrung des verfahrens.
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
JPS58118008A (ja) 1982-01-06 1983-07-13 Nec Corp デ−タ処理装置
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
US4943529A (en) 1982-05-19 1990-07-24 Gist-Brocades Nv Kluyveromyces as a host strain
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4558005A (en) 1982-09-13 1985-12-10 University Patents, Inc. Monoclonal anti-erythropoietin
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4710457A (en) 1983-06-29 1987-12-01 Sloan-Kettering Institute For Cancer Research Monoclonal antibody for human hematopoietic glycoproteins and method
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
AU3145184A (en) 1983-08-16 1985-02-21 Zymogenetics Inc. High expression of foreign genes in schizosaccharomyces pombe
EP0350973B1 (de) 1983-09-26 1997-11-05 Udo Dr. Ehrenfeld Mittel und Erzeugnis für die Diagnose und Therapie von Tumoren sowie zur Behandlung von Schwächen der zelligen und humoralen Immunabwehr
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
EP0143949B1 (de) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmazeutische Zusammensetzung mit Gehalt an Urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
EP0266032A1 (de) 1986-08-29 1988-05-04 Beecham Group Plc Modifiziertes fibrinolytisches Enzym
IL87737A (en) 1987-09-11 1993-08-18 Genentech Inc Method for culturing polypeptide factor dependent vertebrate recombinant cells
GB8724885D0 (en) 1987-10-23 1987-11-25 Binns M M Fowlpox virus promotors
EP0321196A3 (de) 1987-12-18 1990-07-18 Mycogen Plant Science, Inc. Transkriptionsaktivator des 780 T-DNA-Gens
WO1989005859A1 (en) 1987-12-21 1989-06-29 The Upjohn Company Agrobacterium mediated transformation of germinating plant seeds
US5258287A (en) 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
AU4005289A (en) 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
WO1990003430A1 (en) 1988-09-23 1990-04-05 Cetus Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (de) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformationsvektoren für Hefe Yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DK168302B1 (da) 1989-06-29 1994-03-07 Danisco Fremgangsmåde til indføring af molekyler, især genetisk materiale i planteceller
FR2649120B1 (fr) 1989-06-30 1994-01-28 Cayla Nouvelle souche et ses mutants de champignons filamenteux, procede de production de proteines recombinantes a l'aide de ladite souche et souches et proteines obtenues selon ce procede
DE69024369T2 (de) 1989-11-22 1996-06-13 Genentech, Inc., South San Francisco, Calif. Latenz assoziierte peptide und deren verwendung
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2119930C (en) 1991-09-23 2002-10-01 Hendricus R. J. M. Hoogenboom Production of chimeric antibodies - a combinatorial approach
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5635177A (en) 1992-01-22 1997-06-03 Genentech, Inc. Protein tyrosine kinase agonist antibodies
EP0656941B1 (de) 1992-03-24 2005-06-01 Cambridge Antibody Technology Limited Verfahren zur herstellung von gliedern von spezifischen bindungspaaren
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
CA2175892C (en) 1993-11-23 2000-03-07 Paul J. Godowski Kinase receptor activation assay
EP0731842A1 (de) 1993-12-03 1996-09-18 Medical Research Council Rekombinante indungsproteine und -peptide
GB2285446B (en) 1994-01-03 1999-07-28 Genentech Inc Thrombopoietin
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
US5571686A (en) 1994-04-14 1996-11-05 Massachusetts Institute Of Technology Method of using megapoietin for prolonging the survival & viability of platlets
US5885574A (en) 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
JPH09289892A (ja) 1996-04-25 1997-11-11 Yamanouchi Pharmaceut Co Ltd ｃ−ＭＰＬリガンドアゴニスト抗体
US5980893A (en) 1997-07-17 1999-11-09 Beth Israel Deaconess Medical Center, Inc. Agonist murine monoclonal antibody as a stimulant for megakaryocytopoiesis

Also Published As

Publication number Publication date
AU8831298A (en) 1999-03-16
ES2304795T3 (es) 2008-10-16
JP2001513999A (ja) 2001-09-11
DE69839270D1 (de) 2008-04-30
US6342220B1 (en) 2002-01-29
EP1009831A2 (de) 2000-06-21
EP1009831B1 (de) 2008-03-19
EP1958965A2 (de) 2008-08-20
DE69839270T2 (de) 2009-04-30
CA2301964A1 (en) 1999-03-04
WO1999010494A3 (en) 1999-05-20
CA2301964C (en) 2012-02-07
AU755822B2 (en) 2002-12-19
WO1999010494A2 (en) 1999-03-04
EP1958965A3 (de) 2010-12-08

Similar Documents

Publication Publication Date Title
DE69839270D1 (de) Agonistische antikörper gegen den thrombopoietinrezeptor und deren therapeutische verwendungen
ATE470714T1 (de) Antikörper gegen doppelintegrinen, zusammensetzungen, verfahren und verwendungen
CY2020003I2 (el) Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις για την θεραπευτικη αγωγη της παθολογιας του crohn
PT800519E (pt) Compostos moduladores de receptores de esteroides e metodos
DE69535459D1 (de) Monoklonale antikörper spezifisch gegen vegf-rezeptoren und ihre verwendung
DE69617896D1 (de) Humaner monoklonaler Antikörper gegen VEGF
DK1047781T3 (da) IL-18-receptorer
DE122012000001I1 (de) Humane antikorper gegen CTLA-4 und deren verwendungen.
BR9609035A (pt) Anticorpos monoclonais de macaco específicos para formas primatizadas B7.1 e/ou B&.2 humanas composições farmacéuticas
DE50212615D1 (de) Lyophilisierte zubereitung enthaltend antikörper gegen den egf-rezeptor
DE69934241D1 (de) Agonistische antikörper gegen tie2
AR035977A1 (es) Inmunoconjugados de anticuerpos cd44 citotoxicos.
EA200001039A1 (ru) Кальцилитические соединения
ATE388168T1 (de) Antikörper gegen den il-8 rezeptor und deren therapeutische verwendungen
ATE362490T1 (de) Monoklonale antikörper gegen den menschlichen ldl-rezeptor, deren herstellung und verwendung
ATE457318T1 (de) Gegen das menschliche bst2 antigen gerichteter monoklonaler antikörper
EA200000198A1 (ru) 2-ациламинопропанамины в качестве антагонистов рецепторов тахикининов
EA200400670A1 (ru) Фармацевтические композиции, содержащие 3,4-пропинопергидропурины, и их применение для блокирования нейронной передачи
DE69841260D1 (de) Bakterielle pheromone und deren verwendungen
AR002996A1 (es) Isoxazolinas mejoradas antagonistas del receptore de fibrinogeno.
DE59310204D1 (de) Spezifische Antikörper gegen aktivierte Plättchen, ihre Herstellung und ihre Verwendung in Diagnose und Therapie
DE69732636D1 (de) Monoklonaler antikörper gegen humanes mp52
DE69817579D1 (de) Monoklonaler Antikörper gegen das humanen CD21 und dessen Verwendungen
FI956041A0 (fi) Kompositiot ja diagnostiset menetelmät, joissa käytetään monoklonaalisia vasta-aineita CD44V6 vastaan

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1009831

Country of ref document: EP